Showing 4391-4400 of 6036 results for "".
- MediPrint Ophthalmics Announces Results from its SIGHT-2 Phase 2b Group 1 Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-results-from-its-sight-2-phase-2b-group-1-clinical-study/2481665/MediPrint Ophthalmics announced it has completed its SIGHT-2 dose-finding phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma. This is the first of potentially three doses in the second study of its clinical program SIGHT (Sustained Innovati
- Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptorhttps://modernod.com/news/reduction-of-eyedrop-volume-for-topical-ophthalmic-medications-with-the-nanodropper-bottle-adaptor/2481663/Nanodropper announced positive results from a research study conducted in collaboration with Leonard Seibold, MD, Professor of Ophthalmology at University of Colorado School of Medicine, which quantified eyedrop volume reduction and bottle life extension with the Nanodropper adaptor compared
- Prevent Blindness Launches Multiple Efforts to Provide Education and Resources on the Effects of Vision Loss and Blindness on Mental Healthhttps://modernod.com/news/prevent-blindness-launches-multiple-efforts-to-provide-education-and-resources-on-the-effects-of-vision-loss-and-blindness-on-mental-health/2481658/Nonprofit group Prevent Blindness is raising awareness on the impact of vision Impairment on mental wellbeing through upcoming focus on Eye Health Summit presentations and web resources. "Because individuals with vision loss can experience a higher prevalence of depres
- Kaustabh Ghosh, PhD, Recognized With Catalyst Award for Innovative AMD Researchhttps://modernod.com/news/dr-kaustabh-ghosh-recognized-with-catalyst-award-for-innovative-amd-research/2481657/Doheny Eye Institute announced that Kaustabh Ghosh, PhD, was recently recognized by non-profits Research to Prevent Blindness (RPD) and the International Retinal Research Foundation (IRRF) with the Catalyst Award for innovative approaches for age-related macular degeneration (AMD). 
- AOS Launches Remote Visual Acuity System Platformhttps://modernod.com/news/aos-launches-remote-visual-acuity-system-platform/2481652/AOS (Advanced Ophthalmic Systems) announced the launch of a new remote visual acuity software platform. The AOS VA software is a synchronous test that requires internet connection and can be used on multiple device types. Using a combination of semi-automated test algorithms a
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy/2481648/EyePoint Pharmaceuticals announced it has completed enrollment in the phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential 9-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). “We are delighted to report the completion of enrollment in
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- Gamesquare Partners with Vivior to Help Gamers Build Healthy Screen Habitshttps://modernod.com/news/gamesquare-partners-with-vivior-to-help-gamers-build-healthy-screen-habits/2481646/GameSquare Holdings announced a multi-year, multi-million dollar partnership with Swiss vision care startup Vivior with the aim of promoting healthy digital habits, according to a company news release. Through content creation, product development, and competition, GameSquare and Vivior
- Optos Announces New Ultra-Widefield Color Image Modality, Providing Additional Retinal Visualizationhttps://modernod.com/news/optos-announces-new-ultra-widefield-color-image-modality-providing-additional-retinal-visualization/2481645/Optos announced it is expanding the optomap ultra-widefield (UWF) retinal imaging modalities in the California FA device to further assist eye care professionals in disease management and treatment planning. In addition to optomap color rg (red/green), sensory red-free, c
- Alimera Completes Recruitment for Its NEW DAY Study Evaluating Iluvien for DMEhttps://modernod.com/news/alimera-completes-recruitment-for-its-landmark-new-day-study/2481633/Alimera Sciences announced that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone acetonide intravitreal implant, 0.19mg) as a baseline therapy in p